$EBS

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

Emergent BioSolutions (EBS) reported Q2 2026 revenue of $234.3 million, up 66% year over year, driven by accelerated U.S. government MCM contract modifications. Net loss widened to $180.2 million due to a $191.3 million non-cash Naloxone impairment. Adjusted EBITDA rose to $96.5 million. The company cut 2026 guidance and announced restructuring, including wet lab closures and about 93 job reductions.

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ebs202606-30ex99er.htm EX-99.1 Document EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS • Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior year • Second Quarter 2026 Net Loss of $180.2 million worsening 1,402%

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. ebs-20260626 0001367644 false 0001367644 2026-06-26 2026-06-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Emergent BioSolutions reported Q1 2026 revenue of $156 million, exceeding guidance, with an adjusted EBITDA of $36 million, driven by strong MCM performance and strategic international diversification. The company reduced its net debt by 22% in 2025 and aims for further improvement, while expanding its MCM business and pursuing accretive external opportunities, including a manufacturing partnership with SAB Biotherapeutics. Emergent also highlighted its continued leadership in the Narcan market and efforts to expand access and awareness for overdose prevention.

Emergent BioSolutions is expanding access to NARCAN® Nasal Spray by launching a new carrying case and multipack options, alongside a college campus outreach program. These initiatives aim to increase preparedness for opioid overdoses and reduce associated stigma, particularly among young adults. The company partnered with Pro Football Hall of Famer Emmitt Smith and Release Recovery Founder/CEO Zac Clark for an engagement at Southern Methodist University to promote awareness and education.

Emergent BioSolutions (NYSE: EBS) has secured over $60 million in new orders for smallpox medical countermeasures. This includes a $54 million contract option with the U.S. government for CNJ-016 (VIGIV) and $6.6 million in orders from an international government partner for ACAM2000. Additionally, the company referenced multi-year agreements with Canada valued up to $140 million CAD, with more than $35 million CAD expected in 2026.

Emergent BioSolutions Inc. will hold a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss its financial results for the fourth quarter and full year of 2025. Participants can access the call via webcast on the Investors page of Emergent’s website or by registering in advance for telephone participation. Emergent BioSolutions focuses on protecting public health by delivering life-saving solutions for various health threats.

Emergent BioSolutions announced a voluntary prepayment of $100 million on its term loan facility in late December 2025, using cash on hand. This action reduces the company's gross debt by $275 million since 2023, totaling $593 million, representing a 32 percent decline since the start of its multi-year transformation plan. This move aims to improve Emergent's financial position, enhance flexibility, and support long-term stability and growth.

Revealing a significant insider sell on November 10, Tyagi Sujata Dayal, Director at Emergent BioSolutions ( NYSE:EBS ) , as per the latest SEC filing. What Happened: Dayal's recent move involves selling 8,552 shares of Emergent BioSolutions. This information is documented in a Form 4 filing ...